Company Overview and News

14
FOCUS-As China builds biotech sector, cash floods U.S. startups

10m reuters
SAN FRANCISCO/HONG KONG (Reuters) - For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.
BABA GSK GSK

23
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

2018-09-19 zacks
AstraZeneca (AZN - Free Report) announced positive long-term safety and efficacy data on Fasenra (benralizumab) from the phase III BORA extension study, evaluating the drug as an add-on maintenance treatment for severe eosinophilic asthma patients who were previously treated in pivotal SIROCCO or CALIMA studies.
AZN AMGN UNP TEVJF AZN TEVA GSK TEVVF GSK

4
Should Value Investors Consider Glaxo (GSK) Stock Now?

2018-09-19 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
GSK GSK

11
PRESS DIGEST- Financial Times - Sept 19

2018-09-19 reuters
Sept 19 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
GSK SBUX GSK

5
Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved

2018-09-18 seekingalpha
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticals’s (ALNY) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation.
AGN KPTI THERF GSK PFE GSK BCDA ALNY

5
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

2018-09-17 zacks
GlaxoSmithKline (GSK - Free Report) announced that its HIV-focused company, ViiV Healthcare submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (Tivicay) and lamivudine (Epivir) for the treatment of HIV-1 infection.
GSK GSK PFE

4
GSK's 2-Drug Combo For HIV Could Threaten Gilead

2018-09-17 seekingalpha
GSK's long-acting injection given once a month has proven it can control the AIDS virus as effectively as standard daily pills.
GLAXF GLXQY GLXKY GSK GSK

4
Lupin stock rises over 2% on zero observations for Nagpur unit after USFDA inspection

2018-09-14 moneycontrol
Lupin share price gained 2.4 percent intraday on Friday after the US health regulator concluded the inspection of company's Nagpur unit with zero observations.
GSK GSK

4
Gilead's Rheumatoid Arthritis Drug Successful in Phase III

2018-09-12 zacks
Gilead Sciences, Inc. (GILD - Free Report) and partner Galapagos NV (GLPG - Free Report) announced that the phase III FINCH 2 study on rheumatoid arthritis candidate, filgotinib, was successful.
GILD GLPG GSK LB GSK

40
Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

2018-09-12 seekingalpha
But for PMD, Big pharma drug makers and biotech continued to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.
GRFS ACET GILD AZN MCK CVS GSK SNY AZN AGN PMD NVS GSK ABBV CAH PFE ABBV

4
Lupin gets booster nod from USFDA

2018-09-12 thehindubusinessline
Lupin on Wednesday said it has received nod from the US Food and Drug Administration to market its Atovaquone oral suspension in the strength of 750 mg/5 mL. The product is a generic version of GlaxoSmithKline LLC’s Mepron oral suspension in the same strength, it added.
GSK GSK

4
Lupin gets USFDA nod to market Atovaquone oral suspension

2018-09-12 moneycontrol
Drug firm Lupin Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
GSK GSK

4
Xenon: An Updated Investment Analysis

2018-09-10 seekingalpha
Today, we look at Xenon, a Canadian biopharma whose stock has soared so far in 2018.
XENE GSK GSK

5
Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD

2018-09-10 zacks
GlaxoSmithKline plc (GSK - Free Report) announced that the FDA has issued a complete response letter (CRL) to its supplemental biologics license application (sBLA) for label expansion of its asthma drug, Nucala for a new indication — eosinophilic chronic obstructive pulmonary disease (COPD).
HIK NVS GSK GSK

22
Once-in-a-lifetime deal-making spree underway in India

2018-09-10 livemint
Mumbai: The biggest mergers and acquisitions (M&A) boom in Indian history has investment bankers preparing for even more deal-making to come. Transactions involving Indian companies have reached $104.5 billion in 2018, trouncing the previous annual record with almost four months left in the year, according to data compiled by Bloomberg. The tally may surpass $100 billion again in 2019, said Sanjeev Krishan, a Gurgaon-based partner at PwC India who focuses on private equity and deals.
523405 NMR BHUSANSTL 500470 8604 NRSCF GSK MS 500055 JMFINANCIL GSK BRK.A BABA TTST N33 TATASTEEL TATLY 0700 KHC

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to LSE:GSK / GLAXOSMITHKLINE on message board site Silicon Investor.

After Glaxou0027s genital herpes vaccine flop, check out Agenus After Glaxou0027s genital herpes vaccine flop, check out Agenus After Glaxou0027s genital herpes vaccine flop, check out Agenus SI Pigskin Pick em SI Pigskin Pick em SI Pigskin Pick em
FOOTBALL: 1999 Pigskin Prognostication Contest FOOTBALL: 1999 Pigskin Prognostication Contest FOOTBALL: 1999 Pigskin Prognostication Contest TGSK - Great White Marine u0026 Recreation, Inc. TGSK - Great White Marine u0026 Recreation, Inc. TGSK - Great White Marine u0026 Recreation, Inc.
FOOTBALL: 1998 Pigskin Prognostication Contest FOOTBALL: 1998 Pigskin Prognostication Contest FOOTBALL: 1998 Pigskin Prognostication Contest